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Risk of diarrhea in a long-term cohort of renal transplant patients given 
mycophenolate mofetil: the significant role of the UGT1A8*2 variant allele. 
 
J.B. Woillard
1,2*
 and J.P. Rerolle
1,4*
, N. Picard
1,2,3
, A. Rousseau
1,2
, M. Drouet
5,6
, E. 
Munteanu
4
, M. Essig
1,4
, P. Marquet
1,2,3
, Y. Le Meur
1,7 
 
1
Inserm, UMR S-850, Limoges, France; 
2
Univ Limoges, Limoges, France; 
3
CHU 
Limoges, Service de Pharmacologie et Toxicologie, Pharmacovigilance, Limoges, 
France ; 
4
CHU Limoges, Service de Néphrologie, Limoges, France ; 
5
CHU Limoges, 
Service d’Immunologie, Limoges, France ; CNRS UMR 6101, Limoges, France ; 7CHU 
Brest, Hôpital de la Cavale Blanche, Service de Néphrologie, Brest, France.  
 
*These authors contributed equally to this work. 
Correspondence should be addressed to P. Marquet, INSERM U850, 2 rue du Dr 
Marcland, 87025 Limoges, France 
Tel: +33555435895; fax: +33555435936 
e-mail: pierre.marquet@unilim.fr 
Running head: Pharmacogenetics of mycophenolate-induced diarrhea  
Keywords: Kidney transplantation, mycophenolate mofetil, pharmacogenetics, 
diarrhea, uridine diphosphate-glucuronosyltransferase, UGT1A8*2 
 
Word count: 3709 words 
3 tables and 4 figures 
 2 
What is already known about this subject 
- Mycophenolate mofetil (MMF), the most widely used drug in allograft 
transplantation, is subject to hepatic and intestinal glucuronidation and entero-
hepatic cycling. 
- Diarrhea is its most frequent adverse event leading to non-compliance, treatment 
interruption and ultimately to an increased rate of acute rejection. 
- Cyclosporine reduces the biliary excretion of mycophenolate metabolites, 
presumably by inhibiting the efflux transporter MRP2 
- When combined with MMF, cyclosporine reduces the incidence of diarrhea, 
suggesting the role played by biliary excretion of mycophenolate glucuronides 
in this adverse event. 
What this study adds 
- In a long term cohort of renal transplant patients on MMF, the two factors 
significantly associated with a reduced incidence of diarrhea were: the co-
medication with cyclosporine (as opposed to tacrolimus or sirolimus), and the *2 
variant allele of the intestinal UGT1A8. 
- Polymorphisms in the others UDP-glucuronosyl-transferase and MRP2 were not 
significant. 
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Summary 
Aim: In renal transplant patients given mycophenolate mofetil (MMF), we investigated 
the relationship between the digestive adverse events and polymorphisms in the UGT 
genes involved in mycophenolic acid (MPA) intestinal metabolism and biliary excretion 
of its phase II metabolites.  
Methods: Clinical data and DNA from 256 patients transplanted between 1996 and 
2006 and given MMF with cyclosporine (CsA, n=185), tacrolimus (TAC, n=49) or 
sirolimus (SIR, n=22), were retrospectively analyzed. The relationships between 
diarrhea and polymorphisms in UGT1A8 (*2 518C>G, *3 830G>A), UGT1A7 
(622C>T), UGT1A9 (-275T>A), UGT2B7 (-840G>A) and ABCC2 (-24C>T, 3972C>T) 
or the co-administered immunosuppressant were investigated using the Cox 
proportional hazard model.  
Results: Multivariate analysis showed that patients on TAC or SIR had a 2.8 higher risk 
of diarrhea than patients on CsA (HR=2.809; 95%CI (1.730-4.545); p<0.0001) and that 
non-carriers of the UGT1A8*2 allele (CC518 genotype) had a higher risk of diarrhea 
than carriers (C518G and 518GG genotypes) (HR=1.876; 95%CI (1.109-3.175); 
p=0.0192). When patients were split up with respect to the immunosuppressive co-
treatment, a significant effect of UGT1A8*2 was found in those co-treated with 
cyclosporine (HR=2.414; 95%CI (1.089-5.354); p=0.0301) but not TAC or SIR 
(p=0.4331). 
Conclusion: These results suggest that a possible inhibition of MPA metabolites biliary 
excretion by cyclosporine and a decreased intestinal production of these metabolites in 
UGT1A8*2 carriers may be protective factors against MMF-induced diarrhea. 
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Introduction 
Mycophenolate mofetil (MMF), the prodrug of mycophenolic acid (MPA), is an 
immunosuppressive drug widely used in combination therapy with cyclosporine (CsA), 
tacrolimus (TAC) or sirolimus (SIR) for the prevention or the treatment of acute 
rejection following kidney, heart and liver allograft transplantation.  
The main adverse events (AE) reported for MPA are gastrointestinal (GI) disorders (in 
particular diarrhea), bone marrow suppression and anemia (1, 2). MMF would be 
discontinued in 20% of the patients because of such adverse events (3). It was first 
hypothesized that MMF digestive adverse events could be related to MMF dose and/or 
to MPA plasma levels (4, 5) but this was not confirmed by a further study (6). Other 
hypotheses include the possible predisposition of patients to MMF diarrhea in relation 
to MPA metabolism, and drug-drug interactions. The metabolism of MPA is mainly by 
conjugation of its phenol group to give the inactive MPA-phenyl-glucuronide (MPAG) 
(7) which involves UGT1A9, and to a lower extent UGT1A7, 1A8 and 1A10 (8, 9). The 
conjugation of MPA carboxylic acid moiety leads to a second glucuronide, namely 
MPA-acyl-glucuronide (AcMPAG) (10), which is mainly produced by UGT2B7 in the 
liver and, to a lower extent, in other tissues including the intestine and the kidneys (8). 
MMF induces a particular type of diarrhea, the exact mechanism of which remains 
unknown. Several authors reported that the normal villous structure of the small bowel 
was lost (11-13). Owing to the reactivity of AcMPAG (14)
,
(15), it was suggested that 
AcMPAG could be involved in this adverse event through a secondary immunological 
mechanism (16). However, neither MPAG nor AcMPAG plasma exposures were 
associated with diarrhea in a study in kidney transplants patients (6), where the only 
significant factor found was the calcineurin inhibitor associated to MMF: a lower 
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incidence of diarrhea was observed in patients co-treated with CsA than in those co-
treated with TAC. As CsA inhibits the Multidrug Resistance Protein 2 (MRP2)-
mediated excretion of MPA metabolites into the bile (17), it suggests that biliary 
excretion of MPA metabolites, hence intestinal exposure to these metabolites would be 
more closely linked with diarrhea than systemic exposure.  
The aim of this study was to investigate in a long-term cohort of renal transplant 
patients on MMF the influence on digestive adverse events of: (i) polymorphisms of the 
genes encoding the UGTs involved in MPA intestinal metabolism (UGT1A7, UGT1A8, 
UGT1A9 and UGT2B7); (ii) polymorphisms of the gene encoding the efflux transporter 
involved in the biliary excretion of MPA metabolites (ABCC2); and (iii) co-
administered immunosuppressants. 
 
Methods 
Patients 
The clinical data-on-file and banked DNA samples from patients transplanted between 
1996 and 2006, routinely followed as outpatients at Limoges University hospital were 
retrospectively studied. The ethics committee of Limoges hospital approved the 
protocol. Informed consent was obtained from each living patient, while the French 
Health Authorities have waived the requirement for consent for deceased patients. The 
following inclusion criteria were used: recipient age > 18 years; functioning graft after 
more than one year posttransplantation; kidney graft from a cadaveric donor; 
constitutional DNA available; deceased patient or signed informed consent. Exclusion 
criteria were as follows: patient age < 18 years, pregnancy, graft survival < 1 year and 
kidney and pancreas, heart or liver combined transplantation. For each patient, the 
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following clinical data were recorded from the medical file by the same nephrologist 
(JPR): date of birth, sex, HLA mismatches between donor and recipient, duration of 
cold ischemia, induction therapy, immunosuppressive drug regimens and 
gastrointestinal adverse events (GI AEs), with their starting and ending dates. The GI 
AEs were classified as diarrhea, abdominal pain, nausea/vomiting and anorexia. In 
order to reduce the number of statistical tests and because of the low frequencies of 
abdominal pain (11.0%), nausea/vomiting (5.5%) and anorexia (7.0%), only diarrhea 
(27.7%) and the global incidence of all GI AEs (35.1%) were finally analyzed. Clinical 
data collection was performed before the initiation of the genetic study to avoid any 
bias. Diarrhea was taken into consideration when sufficient and convincing data was 
available in the clinical file, in particular regarding the duration, severity and resolution 
of the diarrhea episode, and when it most likely fulfilled the following definition: more 
than 2 loose, watery stools per day persisting for more than five days, without fever or 
inflammatory disease, or any other patent etiology (positive viral or cytobacterial or 
parasitological examination of the stools when available and treatments known to 
provoke diarrhea, other than immunosuppressive therapy) and/or when the episode 
stopped after MMF dose reduction or discontinuation. Patients were treated following 
the medical practice at that time in Limoges University Hospital. 
Genomic DNA bank 
DNA collection and conservation was performed by the immunogenetic laboratory of 
Limoges University Hospital. Genomic DNA was extracted from EDTA-treated blood 
using a previously described manual method (18). 
Identification of genotypes 
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Genomic DNA was used to characterize the genotypes of each patient for SNPs in the 
UGT1A7, UGT1A8, UGT1A9, UGT2B7 and ABCC2 (MRP2) genes (table 1). Genotypes 
were determined using Real-Time Quantitative Polymerase Chain Reaction (ABI 
PRISM 7000 Sequence Detection System; Applied Biosystems, Courtaboeuf, France) 
and validated allelic discrimination assays (TaqMan Custom or Drug Metabolism 
Genotyping assays®, Applied Biosystems). 
Briefly, 1 to 20 ng of genomic DNA were mixed with each assay and PCR universal 
master mix (Applied Biosystems, Foster City, CA USA) in a total volume of 14 µL. 
Thermal cycler parameters included 10 minutes at 95°C and 40 cycles of denaturation at 
92°C for 15 seconds and annealing/extension at 60°C for 1 minute, except for UGT1A8 
and UGT1A7 assays which required 1.5 min elongation steps and 45 PCR cycles. 
Statistical analysis  
Deviations from the Hardy-Weinberg equilibrium were studied using the Fisher exact 
test. The effect of the polymorphisms (SNPs or haplotypes) on phenotypes was 
investigated using the Cox proportional hazard model, considering successively all GI 
AEs and diarrhea only. P values less than 0.05 were considered significant and 95% 
confidence intervals provided when relevant. For SNP and haplotype association 
analyses, the most frequent allele was considered as the reference. When the frequency 
of variant homozygous patients was lower than 5%, these patients were gathered with 
the heterozygotes. For multivariate analysis, the significance of variables in the final 
model was tested by a backward stepwise process using the likelihood ratio to evaluate 
the effect of omitting variables. After studying the effect of each polymorphism 
independently, the association of haplotypes with GI AEs was analyzed using the 
THESIAS program (http://genecanvas.ecgene.net) (19) when appropriate. 
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The ABCC2 polymorphism was investigated in 2 subgroups of treatment independently: 
CsA and TAC /SIR because of the hypothesis of ABCC2 biliary inhibition by CsA. 
In order to investigate the effect of MMF dose on the incidence of diarrhea, the dose at 
the time of the first episode of diarrhea in “case” patients was compared to the dose 
collected at a similar time after initiation of MMF in “control” patients paired on 
follow-up duration while on MMF. Dose was classified into 4 groups (≤750, 1000, 1500 
or ≥2000) and compared using the Fisher exact test, then in two groups (<2g or >=2g) to 
be analyzed using the Cox model. For significant covariates, time-to-event data (first 
episode) were estimated using Kaplan-Meier analysis for patients with or without the 
factor of interest, and groups were compared by the log-rank test. 
 Except when stated otherwise, all statistical analyses were performed using Statview 
5.0 (SAS Institute Inc, Cary, NC, USA). 
 
Results 
Clinical Data 
The clinical and demographic characteristics of the 256 patients who fulfilled the 
inclusion and exclusion criteria (out of 386 patients transplanted at Limoges University 
Hospital over the period 1996-2006) are described in table 2. Patients’ follow up was 
41.0 months on average (ranging from 0.6 to 115.0). Each patient was taken into 
consideration as from the initiation of MMF treatment, which corresponded to the first 
days posttransplantation in 222 patients (86.7%). The 34 others were switched from 
azathioprine to MMF in the stable post-transplantation period. During the study period, 
a total of 194 episodes of gastrointestinal adverse events (GI AEs) were observed in 90 
patients (35.1%), including 118 episodes of diarrhea in 71 patients (27.7%). Twenty 
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five patients had more than 2 episodes of diarrhea. The mean MMF dose at the time of 
the episode was 1750±699 g in the group with diarrhea (cases) and 1768±443 g in the 
group without (controls) (ns). Among patients with diarrhea, there was a significant 
difference in MMF dose between patients co-treated with TAC (1278±521 mg) and 
those co-treated with either SIR (1889±333 g) or CsA (1927±738 g) (p=0.0026). 
 
Linkage disequilibrium study 
All the genotype distributions were in conformity with the Hardy-Weinberg equilibrium 
and similar to those reported in the literature (table 1). A strong linkage disequilibrium 
(LD) was observed between the ABCC2 -24C>T and the 3972C>T Single Nucleotide 
Polymorphisms (SNPs) (D’=0.93, R²=0.41). Four haplotypes were found: -24C/3972C 
(59.6%), -24T/3972T (22.5%), -24C/3972T (16.9%) and -24T/3972C (1.0%). No LD 
was observed between the UGT SNPs. 
 
Effects of co-administered immunosuppressant and MMF dose 
The percentage of patients with diarrhea was 17.8%, 54.5% and 53.1% in the CsA, SIR 
and TAC subgroups, respectively (table 2). There was no difference in the incidence of 
diarrhea between patients on TAC or SIR (Cox model: p=0.5789) (Fig.1). 
Consequently, due to the rather small number of patients in these subgroups (n = 49 and 
22, respectively), they were combined for comparison to CsA co-treated patients. 
Univariate analysis using the Cox model showed a highly significant association of the 
co-administered immunosuppressant with diarrhea (TAC/SIR vs CsA: Hazard Ratio 
(HR)=4.251; 95%CI (2.637-6.853); p<0.0001) (table 3), as well as with the GI AEs 
studied globally (TAC/SIR vs CsA: Hazard Ratio (HR)=3.788; 95%CI (2.457-5.848); 
p<0.0001).  
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No significant association was found between GI AEs and MMF dose at the time of the 
event, whether the dose was considered in four groups (≤750, 1000, 1500, ≥2000; 
Fisher exact test p=0.095) (Fig. 2), or in two groups (<2000 and ≥2000: Hazard Ratio 
1.146; CI95% (0.702-1.869); p=0.5861) (table 3).  
 
Survival analysis 
For patients with more than 1 episode of diarrhea, only the first episode was taken into 
account. Kaplan Meier analysis of the time to the first episode of diarrhea demonstrated 
a significantly higher incidence in carriers of at least one UGT1A8*2 variant allele (Fig. 
3A; p=0.0101). Similar results (Fig. 3B; p=0.0352) were obtained when only the 
patients who started MMF in the first days posttransplantation (n=222) were considered, 
while a similar trend, with a seemingly even larger difference (Fig. 3C; p=0.1448) was 
observed in the others, who started MMF later after transplantation (n=34). The Kaplan 
Meier analysis of the time to the first episode of diarrhea  shows a significantly higher 
incidence in patients co-treated with TAC/SIR than in patients co-treated with CsA (Fig. 
1; p<0.0001). Similar results were obtained for the GI AEs studied globally (data not 
shown, p<0.0001). No difference in the Kaplan Meier analysis of the time to graft loss 
was found between patients with and without diarrhea (p=0.3016), nor with and without 
GI AEs studied globally (p=0.1641). 
 
Pharmacogenetic association 
Considering again the first episode of diarrhea, univariate analysis showed non-carriers 
of UGT1A8*2 had a significantly higher incidence of diarrhea than heterozygous or 
homozygous carriers of the allele (HR=1.968; 95%CI (1.163-3.322); p=0.0117). 
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However, this SNP was not associated with GI AEs considered as a whole (HR=0.803, 
95%CI (0.559-1.154); p=0.2365). No significant associations were found between 
UGT1A7 (622C>T), UGT1A8*3 (830G>A), UGT1A9 (-275T>A), UGT2B7 (-840G>A) 
or ABCC2 (-24C>T, 3972C>T) SNPs and all GI AEs (data not shown) or diarrhea (table 
3). The influence of the main ABCC2 haplotypes compared to the most frequent 
haplotype (-24C/3972C), called here CC, was not significant on diarrhea (table 3) or GI 
AEs as a whole (data not shown), neither when considering all patients together, nor 
when considering patients on CsA or patients on TAC or SIR separately (data not 
shown). 
A multivariate Cox model taking into consideration in the same model the co-
administered immunosuppressant and the UGT1A8 genotype showed that the patients 
on tacrolimus or sirolimus had a 2.8-fold higher risk of diarrhea than the patients on 
CsA (HR=2.809; 95%CI (1.730-4.545); p<0.0001), while non-carriers of UGT1A8*2 
had a 1.9-fold higher risk of diarrhea as compared to homozygous or heterozygous 
carriers (C518G or 518GG genotypes) (HR=1.876; 95%CI (1.109-3.175); p=0.0192).  
In order to evaluate the respective role of the UGT1A8*2 allele and the 
immunosuppressive co-treatment over time, four groups were set up and further 
compared using the Cox model: the patients co-treated with CsA and carrying at least 
one UGT1A8*2 allele had the lowest incidence of diarrhea, followed in increasing order 
of incidence by patients with: CsA and no UGT1A8*2 allele (HR=2.414; 95%CI (1.089-
5.354); p=0.0301); TAC or SIR and one or two UGT1A8*2 allele (HR=6.287; 95%CI 
(2.503-15.792); p<0.0001); and TAC or SIR and no UGT1A8*2 allele (HR=8.332; 
95%CI (3.769-18.417); p<0.0001) (Fig. 4). However, there was no significant 
association between the risk of diarrhea and UGT1A8*2 in patients co-treated with TAC 
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or SIR (UGT1A8*2 carriers vs. non-carriers: HR=0.755; 95%CI (0.373-1.526); 
p=0.4331).  
 
Discussion 
Based on the data collected retrospectively in 256 renal transplant patients receiving 
MMF, we found that patients given tacrolimus or sirolimus or non-carriers of 
UGT1A8*2 had a higher incidence of diarrhea than those given cyclosporine or carrying 
the UGT1A8*2 allele, respectively. Several studies investigated the relations between 
gene polymorphisms of the UGTs or efflux transporters and interindividual variability 
of MMF exposure, but only a few focused on the direct association of these 
polymorphisms with MMF-related AEs. Here we studied the potential link of these 
genes with the occurrence of MMF-related diarrhea episodes. The low numbers of other 
kinds of AEs prevented us from performing statistical analyses for each of them.  
The co-administered calcineurin was also taken into consideration, since cyclosporine is 
known to influence MMF pharmacokinetics through drug-drug interactions and 
tacrolimus to induce diarrhea. To the best of our knowledge, this is the first 
pharmacogenetic study of MMF-related toxicity in a long-term cohort of renal 
transplant patients. The number of patients studied over this extended period (1996 to 
2006) represents a large sample of the renal transplant population in our center.  
MMF-related diarrhea was the major digestive AE reported in the patients’ files.  
Diarrhea was previously described as the main digestive AE of MMF (20), with 
frequencies close to those observed herein (15% when associated with CsA and 38% 
with TAC) (6). The role of MMF in diarrhea episodes occurring in transplant patients is 
difficult to ascertain since numerous etiologies could result in similar symptoms. In this 
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study, all the clinical files were retrospectively screened by one individual nephrologist, 
allowing a homogenous definition and report of this AE. It excluded clinically evident 
infectious diarrheas. Moreover, CMV antigen or PCR were negative at the time of 
diarrhea in all patients. Because examination of the stools or extensive biological work-
up was not systematically performed, we cannot exclude misclassification in some cases 
as suggested by the study of Maes et al.(13). However, diarrheas of infectious origin 
usually do not disappear after MMF dose reduction. Furthermore, misclassification in 
the present study, if any, must have been similar in the different genotypic groups and 
would only result in a loss of statistical power and not in a statistical bias. Similarly, the 
environmental factors which can also be associated with diarrhea (not investigated 
herein) may also have resulted in a loss of power but in no bias, which can only 
emphasize our findings. 
Before MMF release, it had already been reported that patients under TAC had a higher 
incidence of diarrhea than patients under CsA: in a multicenter randomized trial 
comparing TAC versus CsA in association with azathioprine and steroids, the one year 
incidence of diarrhea was twice as much in TAC patients (21.8% vs 10.3%; p<0.005) 
(21). In comparison, the incidence here was higher, at 53.1%, 54.5% and 17.8% for 
TAC, SIR and CsA, respectively, suggesting that MMF represents an independent risk 
factor of diarrhea. This study shows that the associated immunosuppressant is the main 
factor associated with diarrhea in patients on MMF: CsA was associated with approx. a 
2.8-fold lower risk of diarrhea as compared to SIR or TAC. Similar results were 
previously reported by Heller et al. who found that renal transplant patients receiving 
MMF in combination with TAC have a 2.4 higher incidence of diarrhea than those on 
CsA (n=110). It was also previously demonstrated that patients receiving MMF in 
 14 
combination with SIR or TAC were exposed to higher plasma concentrations of MPA 
than those with CsA (22-24). CsA presumably decreases MPAG biliary excretion by 
inhibiting MRP2, as suggested by data from mutant rats not expressing MRP2 (17). 
Consequently, less MPAG is subject to deconjugation by the intestinal flora, resulting in 
decreased re-circulation of MPA, impacting its plasma levels. However, several studies 
failed to demonstrate any direct association between plasma levels of MPA or MPA 
metabolites and MMF related AE (6), including the Apomygre trial where the incidence 
of MMF related GI AEs was identical in the two protocol arms despite significantly 
higher MPA exposure over the first three months post-transplantation in the 
concentration-controlled group (25). This suggests that the decreased risk of MMF-
related diarrhea in patients receiving CsA as compared to SIR or TAC would be more 
related to a local mechanism. CsA might decrease intestinal exposure to 
MPAG/AcMPAG, as well as to MPA (derived from intestinal hydrolysis of these 
metabolites), which could result in a lower risk of diarrhea by a yet unknown 
mechanism. A potential limitation of the present work is that we did not investigate 
MPA exposure as a covariate in the multivariate analysis, due to the fact that, apart from 
patients included in clinical trials, the determination of MPA levels was not regularly 
performed in this retrospective cohort, in particular before 2002. Another limitation is 
that no detailed information was available about the diarrhea intensity and its evolution 
after treatment modification (if any).  
Noteworthy, the sex ratio was different between the 3 groups of associated 
immunosuppressant (p=0.01). This difference may be explained by the physicians’ 
prescription habits as they usually prefer to prescribe tacrolimus instead of cyclosporine 
to female patients because of the well-known risk of hypertrichosis associated with the 
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latter. However, there was no difference in the incidence of diarrhea between males and 
females. 
We observed a longer follow up period for patients co-treated with CsA as compared to 
those co-treated with TAC or SIR, which is due to the fact that cyclosporine was more 
often prescribed than tacrolimus or sirolimus over the first years of the follow-up 
period. 
The daily dose of MMF itself does not seem to influence the risk of diarrhea, although 
in clinical practice, a dose decrement is sometimes used to stop or reduce it. The relative 
risk of the MMF dose, estimated from 121 renal transplants by Borrows et al., was very 
low (1.17 per 1g-increase of MMF dose) (5). In this study, we compared the dose 
received before the adverse events in patients with diarrhea to that of paired patients 
without. Although the pairing strategy did not allow for more than one control per case, 
resulting in a loss of statistical power, the effect of MMF dose was not significant in this 
sub-group of 136 patients, which is consistent with another study where patients who 
suffered from diarrhea had not received a significantly different MMF daily dose than 
those who did not (6). Moreover, we found that patients on tacrolimus had the highest 
incidence of diarrhea although they received a lower MMF dose at the time of diarrhea 
than patients on SRL of CsA. The high reactivity of AcMPAG could possibly contribute 
to MMF GI AEs. Alternatively, the amount of MPA produced in the gut from the 
hydrolysis of MPAG during MPA enterohepatic cycling could also possibly trigger 
local inflammation, although MMF is already partly hydrolyzed to MPA in the gut 
lumen or in intestinal epithelial cells, due to the ubiquity of esterases in the body. In this 
study we investigated the major polymorphisms of the isoforms thought to be involved 
in MPA intestinal metabolism or metabolites excretion and found that patients carrying 
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the UGT1A8*2 allele had a lower risk of diarrhea than homozygous wild-type carriers. 
Bernard et al found that UGT1A8 produces both MPAG and AcMPAG using stably-
expressed enzyme in HEK-293 cells. In their study, cells transfected with UGT1A8*2 
had a decreased capability to produce AcMPAG as compared to UGT1A8*1 (Vmax and 
Clint values were divided by 2) but similar activity for MPAG formation (26) . Thus, the 
lower incidence of MMF-related diarrhea found here in patients carrying the 
UGT1A8*2 allele could possibly be linked to a lower local production of AcMPAG, 
which would prevent its toxicity on the intestinal mucosa. The relative risk of diarrhea 
linked with the co-administered immunosuppressant is greater than that of the UGT1A8 
polymorphism, but the UGT activity might be an important factor in CsA treated 
patients (whose biliary excretion of metabolites is reduced) contrary to patients 
receiving SIR or TAC, as suggested by the ranking of their combined effects (Fig. 4). 
We observed no effect of UGT1A8*2 when GI AEs were studied as the whole, which 
included diarrhea, abdominal pain, nausea/vomiting and anorexia. It was already 
suggested that MMF diarrhea can be due to a local mechanism involving MPA 
glucuronidation. This hypothesis is probably less likely for the other GI AEs. This can 
explain why the results were not similar when studying diarrhea alone or together with 
the other GI AEs. We hypothesized that GI AEs as a whole represented a too 
heterogeneous phenotype, masking the association between diarrhea and the genotype. 
ABCC2 was another good candidate gene in line with our hypothesis, but we did not 
find any significant effect of its SNPs or haplotype on the risk of diarrhea in the whole 
population, or when considering separately patients on CsA and patients on TAC/SIR. 
This last result shows that this absence of genotypic effect is not due to a masking 
MPR2 inhibition, which has been reported for CsA (17) but not for TAC or SIR. 
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In conclusion, the inhibition of the biliary excretion of MPA metabolites by CsA and 
the local production of these metabolites depending on the activity of UGT1A8 may be 
important risk factors of MMF-related diarrhea. The exact mechanisms underlying these 
findings deserve further investigation.  
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Table 1- Frequency and distribution of the polymorphisms studied. 
Gene Polymorphism 
Frequency of the 
variant allele 
Genotype 
wt/wt§ wt/m¤ m/m 
UGT 
622C>T (UGT1A7) 0.627 37/251* 113/251 101/251 
518C>G (UGT1A8*2) 0.226 151/256 94/256 11/256 
830G>A (UGT1A8*3) 0.017 247/256 9/256 0/256 
-275T>A (UGT1A9) 0.055 228/256 28/256 0/256 
-840G>A (UGT2B7) 0.482 73/256 117/256 65/256 
ABCC2 
-24C>T 0.235 148/251* 88/251 15/251 
3972C>T 0.394 82/251* 140/251 29/251 
§wt: wild type. ¤m: variant  
*
5 patients remained undetermined for UGT1A7 and ABCC2 genotypes 
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Table 2- Patients’ characteristics according to the immunosuppressant associated to 
MMF. 
 
 
CsA 
(n=185) 
SIR 
(n=22) 
TAC 
(n=49) 
Male/Female 129/56 9/13 24/25 
Age 
(min/max) 
48.7±14.01 
(17.5/74.3) 
55.3±13.95 
(20.6/72.7) 
47.8±13.03 
(21.8/70.5) 
follow-up 
(min/max) 
48.7±2.5 
(0.7/114.6) 
19.1±4.7 
(0.6/95.0) 
21.9±3.2 
(0.7/115.1) 
Number of patients 
(%) with ≥ 1 
episode of diarrhea 
33 (17.8%) 12 (54.5%) 26 (53.1%) 
Parameters are expressed as mean±SD, age is expressed in years, follow-up period is expressed in months 
and the frequency is given for the number of patients with adverse events; CsA: Cyclosporine, TAC: 
Tacrolimus and SIR: Sirolimus 
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Table 3- Univariate analysis (Cox Model) of the influence of the different variables 
studied on the incidence of diarrhea  
Variable Category¤ 
Hazard 
Ratio* 
CI 95% p 
Number of 
patients 
MMF dose <2 vs>=2 1.146 0.702-1.869 0.5861 68 vs 68* 
Co-administered 
immunosuppressant 
TAC vs CsA 3.817 2.262-6.452 <0.0001 49 vs 185 
SIR vs CsA 4.808 2.463-9.434 <0.0001 22 vs 185 
SIR vs TAC 1.214 0.612-2.408 0.5789 22 vs 49 
SIR/TAC vs CsA 4.251 2.637-6.853 <0.0001 71 vs 185 
UGT1A8*2 
518C>G 
CC vs CG/GG 1.968 1.163-3.322 0.0117 151 vs 94/11 
UGT1A8*3 830G>A GA/AA vs GG 1.190 0.374-3.788 0.7679 9/0 vs 247 
UGT1A7 622C>T 
CC vs TT 0.962 0.465-1.987 0.9161 37 vs 101 
CT vs TT 1.065 0.640-1.772 0.8084 113 vs 101 
UGT1A9 
-275T>A 
TA/AA vs TT 1.389 0.712-2.712 0.3355 28/0 vs 228 
UGT2B7 
-840G>A 
AA vs GG 1.104 0.569-2.142 0.7700 65 vs 73 
AG vs GG 1.245 0.705-2.200 0.4496 117 vs 73 
ABCC2 
-24C>T 
CC vs CT/TT 1.085 0.673-1.751 0.7376 148 vs 88/15 
ABCC2 3972C>T 
CC vs TT 0.765 0.353-1.657 0.4964 82 vs 29 
CT vs TT 0.774 0.374-1.602 0.4901 140 vs 29 
ABCC2 
Haplotype 
-24C>T/3972C>T 
C-T vs C-C 1.271 0.813-1.989 0.2930 
Haplotype 
frequency in 251 
patients : 
CC : 0.47 
CT : 0.30 
TC : 0.14 
TT : 0.09 
T-T vs C-C 0.980 0.523-1.544 0.9324 
T-C vs C-C 0.644 0.098-4.215 0.6463 
*Case-control sub-study. NB. in five patients with diarrhea, the dose could not be taped off. ¤For the most frequent 
category of the variable, taken as reference, HR=1.
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Legends to figures 
 
 
Figure 1 - Kaplan-Meier analysis of the time until the first episode of diarrhea in 
patients on either CsA/MMF, SIR/MMF or TAC/MMF (TAC: Tacrolimus, SIR: 
Sirolimus, CsA: Cyclosporine).  
 
Figure 2 - MMF dose repartition in patients with diarrhea (n=68) and in controls 
(n=68). 
 
Figure 3 - Kaplan-Meier analysis of the time until the first episode of diarrhea 
according to UGT1A8 518C>G genotype (UGT1A8*2). 3A: all patients (n=256); 3B: 
patients who started MMF in the first days posttransplantation (n = 222); 3C: patients 
who were switched from azathioprine to MMF in the stable post-transplantation period 
(n=34). 
 
Figure 4 - Kaplan-Meier analysis of the time until the first episode of diarrhea 
according to the UGT1A8 genotypic groups and immunosuppressive co-treatments 
(TAC: Tacrolimus, SIR: Sirolimus, CsA: Cyclosporine). Cox proportional hazard 
models showed significant differences between: (i) CsA co-treated/UGT1A8*2 carriers 
and CsA co-treated /UGT1A8*2 non-carriers (*p=0.03); (ii) CsA co-treated/UGT1A8*2 
carriers and TAC or SIR co-treated/UGT1A8*2 carriers or non-carriers (§ p<0.0001); 
(iii) CsA co-treated /UGT1A8*2 non-carriers and TAC or SIR co-treated/UGT1A8*2 
carriers or non-carriers (# p<0.01). In patients co-treated with TAC or SIR, no 
significant difference was found between UGT1A8*2 carriers and non-carriers. 
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